

This is a repository copy of CV4 BUDGET IMPACT OF CHANGING ORAL ANTICOAGULANT PRESCRIBING TO PREVENT ATRIAL-FIBRILLATION-RELATED STROKE IN ENGLAND.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/149264/

Version: Accepted Version

Proceedings Paper:

Orlowski, A, Wu, JH orcid.org/0000-0001-6093-599X, Wilkins, J et al. (1 more author) (2019) CV4 BUDGET IMPACT OF CHANGING ORAL ANTICOAGULANT PRESCRIBING TO PREVENT ATRIAL-FIBRILLATION-RELATED STROKE IN ENGLAND. In: Value in Health. ISPOR 2019, 18-22 May 2019, New Orleans, LA, USA. Elsevier, S38-S39.

https://doi.org/10.1016/j.jval.2019.04.037

Copyright © 2019 Published by Elsevier Inc. All rights reserved. Licensed under the Creative Commons Attribution-Non Commercial No Derivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



BUDGET IMPACT OF CHANGING ORAL ANTICOAGULANT PRESCRIBING TO PREVENT ATRIAL-FIBRILLATION-RELATED STROKE IN ENGLAND

Orlowski A1, Jianhua Wu2, Julia Wilkins1, Wayne Smith1

¹Imperial College Health Partners, London, UK, ²University of Leeds, Leeds, UK

OBJECTIVES: A difference-in differences (DiD) showed that prescription of direct oral anticoagulants (DOACs) increased substantially from 2011-2017, while stroke incidence decreased. A budget impact analysis to assess whether these changes affected costs associated with AF-related stroke prevention and care. METHODS: Data on AF-related stroke cases (stroke as primary diagnosis, AF as secondary diagnosis) for all clinical commissioning groups in England were obtained from Hospital Episode Statistics data (copyright NHS Digital 2018). prescribing data from the electronic Prescribing and Costing Tool, and AF detection and treatment data from the Quality and Outcomes Framework data, in the periods 2011-2013 and 2015–2017. The per-patient health-care cost for the first year after a stroke (transport, scans, treatment, care, and rehabilitation) was set at £13,452. The estimated mean drug price for warfarin was £41.32 (excluding the costs of monitoring international normalisation ratio, as these data are not available in England), and for DOACs was £49.00-53.20 per pack. **RESULTS:** The volume of DOACs prescribed increased substantially between the two treatment periods and, accordingly, the total drug prescription costs for oral anticoagulants overall increased by £683.946.537 (983%). The total number of AF-adjusted strokes was reduced by 9.737 (13%) in 2015-2017 versus 2011-2013, which led to a reduction in stroke-associated health-care costs of £130,982,124 (13%). Thus, overall the cost for oral anticoagulant prescribing and care after incident stroke increased by £552,964,413 (151%). CONCLUSIONS: The demonstrated Improvement in stroke prevention with increased DOAC prescribing, although being associated with 13% decrease in stroke incidence, led to nearly a tenfold rise in oral anticoagulant prescribing expenditure. With the likely rise in incidence of AF and AF-related stroke among England's ageing population, these budget impact findings suggest that action is needed to achieve the most efficient use of NHS resources.

294 words